Biology 2013, 2(2), 587-602; doi:10.3390/biology2020587
Review

Antitumor Virotherapy by Attenuated Measles Virus (MV)

1,2,3email, 1,2,3email, 4email and 1,2,3,* email
Received: 4 February 2013; in revised form: 28 February 2013 / Accepted: 5 March 2013 / Published: 28 March 2013
(This article belongs to the Special Issue RNA Viruses and Cancer)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the complement system and is frequently overexpressed by cancer cells to escape lysis by the complement system. MV exhibits oncolytic properties in many cancer types in vitro, and in mouse models. Phase I clinical trials using MV are currently underway. Here, we review the state of this therapeutic approach, with a focus on the effects of MV on the antitumor immune response.
Keywords: antitumor virotherapy; measles virus vaccine; dendritic cells; tumor antigen; clinical trial; vaccine
PDF Full-text Download PDF Full-Text [174 KB, uploaded 28 March 2013 15:17 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Guillerme, J.-B.; Gregoire, M.; Tangy, F.; Fonteneau, J.-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology 2013, 2, 587-602.

AMA Style

Guillerme J-B, Gregoire M, Tangy F, Fonteneau J-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology. 2013; 2(2):587-602.

Chicago/Turabian Style

Guillerme, Jean-Baptiste; Gregoire, Marc; Tangy, Frédéric; Fonteneau, Jean-François. 2013. "Antitumor Virotherapy by Attenuated Measles Virus (MV)." Biology 2, no. 2: 587-602.

Biology EISSN 2079-7737 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert